Abhijeet Anand, Khalequ Zaman, Concepción F. Estívariz, Mohammad Yunus et al.
Introduction: Inactivated poliovirus vaccine (IPV) introduction and phased oral poliovirus vaccine (OPV) cessation are essential for eradication of polio. Methods: Healthy 6-week old infants in Bangladesh were randomized to one of five study arms: receipt of trivalent OPV (tOPV) or bivalent OPV (bOP...
Devy Emperador, Daniel E. Velásquez, Concepción F. Estívariz, Ben Lopman et al.
BACKGROUND: Trivalent oral poliovirus vaccine (OPV) is known to interfere with monovalent rotavirus vaccine (RV1) immunogenicity. The interference caused by bivalent and monovalent OPV formulations, which will be increasingly used globally in coming years, has not been examined. We conducted a post ...
Ashok Choudhury, Anand V. Kulkarni, Vinod Arora, Arvinder Singh Soin et al.
Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set...
Cynthia J. Snider, Khalequ Zaman, Concepción F. Estívariz, Mohammad Yunus et al.
Background Intradermal administration of fractional inactivated poliovirus vaccine (fIPV) is a dose-sparing alternative to intramuscular full dose. We assessed the recommendation of two fIPV doses or one IPV dose for routine immunization, and a fIPV booster dose for outbreak response. Methods We con...
Concepción F. Estívariz, Abhijeet Anand, Howard E. Gary, Mahmudur Rahman et al.
Background The provision of several doses of monovalent type 1 oral poliovirus vaccine (mOPV1) and bivalent OPV1 and 3 (bOPV) vaccines through campaigns is essential to stop the circulation of remaining wild polioviruses. Our study aimed to assess the shortening of intervals between campaigns with b...
Amanda L. Wilkinson, Khalequ Zaman, Masuma Hoque, Concepción F. Estívariz et al.
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine-derived poliovirus type 2 outbreaks. Bivalent oral poliovirus vaccine (bOPV; containing Sabin types 1 and 3) is the vac...
Abhijeet Anand, Imlisongla Aier, Anil Kumar Sakhiya, Priyanka Kaushal
Mallick Masum Billah, K. Zaman, Concepción F. Estívariz, Cynthia J. Snider et al.
Background: Introduction of inactivated polio vaccine creates challenges in maintaining the cold chain for vaccine storage and distribution. Methods: We evaluated the cold chain in 23 health facilities and 36 outreach vaccination sessions in 8 districts and cities of Bangladesh, using purposive samp...
Daniel E Velasquez-Portocarrero, Xiaoqian Wang, Margaret M. Cortese, Cynthia J. Snider et al.
Background A head-to-head comparison of the most widely used oral rotavirus vaccines has not previously been done, particularly in a high child mortality setting. We therefore aimed to compare the immunogenicity of RotaTeq (Merck, Kenilworth, NJ, USA) and Rotarix (GlaxoSmithKline, Rixensart, Belgium...
Khalequ Zaman, Concepción F. Estívariz, Michelle Morales, Mohammad Yunus et al.
Background Monovalent type 2 oral poliovirus vaccine (mOPV2) and inactivated poliovirus vaccine (IPV) are used to respond to type 2 poliovirus outbreaks. We aimed to assess the effect of two mOPV2 doses on the type 2 immune response by varying the time interval between mOPV2 doses and IPV co-adminis...
Concepción F. Estívariz, Cynthia J. Snider, Abhijeet Anand, Lee M. Hampton et al.
Background: We assessed programmatic adaptations and infants' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the routine immunization schedule in Bangladesh. Methods: Using convenience and probability sampling, we selected 23 health facilities, 36 vaccinators, and 336 car...
Khalequ Zaman, Stéphanie Kovacs, Kristin VanderEnde, Asma Binte Aziz et al.
Background: After global oral poliovirus vaccine (OPV) cessation, the Strategic Advisory Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of inactivated poliovirus vaccine (IPV) beginning ≥14-weeks of age to achieve at least 90% immune response. We aimed to compare th...
Cynthia J. Snider, Khalequ Zaman, Amanda L. Wilkinson, Asma Binte Aziz et al.
Background: To inform response strategies, we examined type 1 humoral and intestinal immunity induced by 1) one fractional inactivated poliovirus vaccine (fIPV) dose given with monovalent oral poliovirus vaccine (mOPV1), and 2) mOPV1 versus bivalent OPV (bOPV). Methods: We conducted a randomized, co...
Eric Wiesen, Kathleen Wannemuehler, James L. Goodson, Abhijeet Anand et al.
Despite recommendations from WHO to conduct measles outbreak response vaccination campaigns based on the age distribution of cases at the beginning of an outbreak, few data exist to specifically examine whether the age distribution of cases remains constant over time in a measles outbreak. This anal...
Md Taufiqul Islam, Kashmira Date, Ashraful Islam Khan, Taufiqur Rahman Bhuiyan et al.
BACKGROUND: Cholera remains a public health threat for low- and middle-income countries, particularly in Asia and Africa. Shanchol™, an inactivated oral cholera vaccine (OCV) is currently in use globally. OCV and oral poliovirus vaccines (OPV) could be administered concomitantly, but the immunogenic...
Takudzwa S. Sayi, Umid Sharapov, Zachary Matson, Melissa M. Coughlin et al.
Background The first dose of measles–rubella (MR) vaccine is routinely administered to infants aged 9 months as part of a standard two-dose schedule. However, during large measles outbreaks and in other settings of increased circulation or increased risk, WHO recommends administering a supplementary...
Cynthia J. Snider, Khalequ Zaman, Concepción F. Estívariz, Asma Binte Aziz et al.
In 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended introduction of at least one inactivated poliovirus vaccine (IPV) dose in essential immunization programs. We evaluated systemic humoral and intestinal mucosal immunity of a sequential IPV-bivalent oral poliovirus va...
Khalequ Zaman, Abhijeet Anand
Khalequ Zaman, Abhijeet Anand
Sirawit Hariwon, Panida Thararak, Peerapol Jirapong, Supanida Kaewwong et al.